Dr. Peter Klemm, Ph.D has been the Chief Executive Officer of Applied Proteomics, Inc. since February 7, 2012 and serves as its President. Dr. Klemm served as the Chief Executive Officer and President of Predictive Biosciences Inc. since March 24, 2008. He has extensive experience in building markets for novel high-value diagnostic tests. Dr. Klemm served as Chief Executive Officer of GeneOhm Sciences Inc. since May 2002 and served as its President. He served as Chief Executive Officer of JOMED Inc. He served as Senior Vice President of Research and Development of Gruenenthal GmbH, a European pharmaceutical company, where he established state of the art drug discovery technologies and central analgesic therapies. Dr. Klemm served at Aventis as Senior Scientist within the cardiovascular drug discovery unit. He served as Chairman and Director of Pathwork Diagnostics, Inc. He served as Director of GeneOhm Sciences Inc. He served as Non-Executive Director at Oxford Immunotec Global PLC. He served as Director of Predictive Biosciences, Inc. since March 24, 2008. Dr. Klemm spent one year as a Post-Doctoral fellow at the William Harvey Research Institute in London. Dr. Peter Klemm, Ph.D has been the Chief Executive Officer of Applied Proteomics, Inc. since February 7, 2012 and serves as its President. Dr. Klemm served as the Chief Executive Officer and President of Predictive Biosciences Inc. since March 24, 2008. He has extensive experience in building markets for novel high-value diagnostic tests. Dr. Klemm served as Chief Executive Officer of GeneOhm Sciences Inc. since May 2002 and served as its President. He served as Chief Executive Officer of JOMED Inc. He served as Senior Vice President of Research and Development of Gruenenthal GmbH, a European pharmaceutical company, where he established state of the art drug discovery technologies and central analgesic therapies. Dr. Klemm served at Aventis as Senior Scientist within the cardiovascular drug discovery unit. He served as Chairman and Director of Pathwork Diagnostics, Inc. He served as Director of GeneOhm Sciences Inc. He served as Non-Executive Director at Oxford Immunotec Global PLC. He served as Director of Predictive Biosciences, Inc. since March 24, 2008. Dr. Klemm spent one year as a Post-Doctoral fellow at the William Harvey Research Institute in London.

Blood Disorders & Transfusion